Scientific Publications

THOR-707, an engineered not-alpha IL-2, for the treatment of solid tumors induces strong immunological responses in vivo

March 22-23, 2019

Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy – Endorsed by the American Association for Cancer Research (AACR)

THOR-707: An Engineered IL-2 for the Treatment of Solid Tumors with Superior Pre-Clinical Efficacy and Safety Evidence

November 9, 2018

2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

A semi-synthetic organism that stores and retrieves increased genetic information

November 30, 2017

Y. Zhang, J.L. Ptacin, E.C. Fischer, H.R. Aerni, C.E. Caffaro, K. San Jose, A.W. Feldman, C.R. Turner, F.E. Romesberg. Nature (2017) 551:644-647.